A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 501–600 of 1,008
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 64
Guyon, A., Rousseau, J., Bégin, F.-G., Bertin, T., Lamothe, G., & Tremblay, J. P. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.02.032 · Cited by 57
β-Amyloid oligomers in aging and Alzheimer’s disease
Zahs, K. R., & Ashe, K. H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00028 · Cited by 53
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk
Rosenthal, S. L., Bamne, M. N., Wang, X., Berman, S., Snitz, B. E., Klunk, W. E., Sweet, R. A., Demirci, F. Y., Lopez, O. L., & Kamboh, M. I. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.012 · Cited by 53
“Rare mutations affecting LOAD risk also have been identified with sequencing methods in the APP and PLD3 genes (Bamne et al., 2014, Cruchaga et al., 2014, Jonsson et al., 2012, and Kero et al., 2013).”
BackgroundPhysiological and pathological roles of the γ-secretase complex
Carroll, C. M., & Li, Y.-M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.019 · Cited by 53
Mellott, T. J., Huleatt, O. M., Shade, B. N., Pender, S. M., Liu, Y. B., Slack, B. E., & Blusztajn, J. K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170450 · Cited by 57
Self-citationBeta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Moussa, C. E.-H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1369527 · Cited by 53
van Groen, T., Schemmert, S., Brener, O., Gremer, L., Ziehm, T., Tusche, M., Nagel‐Steger, L., Kadish, I., Schartmann, E., Elfgen, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16565-1 · Cited by 59
“Synthetic and recombinant Aβ(1-42) with >95% purity was purchased as lyophilized powder from Bachem (Germany) and Isoloid (Germany), respectively.”
MethodInfluentialLooking at the Disordered Proteins through the Computational Microscope
Das, P., Matysiak, S., & Mittal, J. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00626 · Cited by 54
Functional effects of protein variants
Vihinen, M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.10.009 · Cited by 65
Satoh, J.-I., Yamamoto, Y., Asahina, N., Kitano, S., & Kino, Y. (2014) · Disease Markers · doi:10.1155/2014/123165 · Cited by 53
Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., Sabbagh, M. N., Yuan, S. H., Rissman, R. A., Pulsifer, M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0983 · Cited by 52
Cognitively healthy centenarians are genetically protected against Alzheimer's disease
Tesi, N., van der Lee, S., Hulsman, M., van Schoor, N. M., Huisman, M., Pijnenburg, Y., van der Flier, W. M., Reinders, M., & Holstege, H. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13810 · Cited by 52
“46,13,50,51 While the main aim of this study was to identify the AD-associated genetic loci that most prominently associated with escaping AD, our study also suggests that genetic comparisons of diseased individuals to those who are resilient to the disease maximize the identified effect sizes.”
BackgroundPrime Editing for Human Gene Therapy: Where Are We Now?
Godbout, K., & Tremblay, J. P. (2023) · Cells · doi:10.3390/cells12040536 · Cited by 65
“This mutation has been shown to prevent Alzheimer’s Disease by reducing the cleavage of APP by beta-secretase [55].”
BackgroundKallop, D. Y., Meilandt, W. J., Gogineni, A., Easley-Neal, C., Wu, T., Jubb, A. M., Yaylaoglu, M., Shamloo, M., Tessier-Lavigne, M., Scearce-Levie, K., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4963-13.2014 · Cited by 54
“DR6, also known as TNFRSF21, is a member of the extended tumor necrosis factor receptor superfamily of surface receptors that can engage caspase-mediated signaling (Pan et al., 1998; Kasof et al., 2001).”
BackgroundHayes, C. D., Dey, D., Palavicini, J. P., Wang, H., Patkar, K. A., Minond, D., Nefzi, A., & Lakshmana, M. K. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-81 · Cited by 52
“The recent discovery of a coding mutation on the APP gene (A673T) which provides significant protection against cognitive decline in both AD patients as well as normal elderly individuals [54] is strong proof of the principle evidence that reducing Ab levels is an effective therapeutic approach for AD.”
BackgroundChang, J. L., Hinrich, A. J., Roman, B., Norrbom, M., Rigo, F., Marr, R. A., Norstrom, E. M., & Hastings, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.029 · Cited by 61
Nagata, K., Takahashi, M., Matsuba, Y., Okuyama-Uchimura, F., Sato, K., Hashimoto, S., Saito, T., & Saido, T. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04238-0 · Cited by 54
Cheon, M., Hall, C. K., & Chang, I. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004258 · Cited by 55
Coassembly of Macrocyclic Amphiphiles for Anti-β-Amyloid Therapy of Alzheimer’s Disease
Pan, Y., Wang, H., Xu, X., Tian, H., Zhao, H., Hu, X., Zhao, Y., Liu, Y., Ding, G., Meng, Q., et al. (2020) · CCS Chemistry · doi:10.31635/ccschem.020.202000561 · Cited by 52
Self-citationRecent Progress in Small Spirocyclic, Xanthene-Based Fluorescent Probes
Keller, S., Kamiya, M., & Urano, Y. (2020) · Molecules · doi:10.3390/molecules25245964 · Cited by 57
Down's syndrome and Alzheimer's disease: towards secondary prevention
Ness, S. L., Rafii, M. S., Aisen, P. S. S., Krams, M., Silverman, W. P., & Manji, H. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3822 · Cited by 52
PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains
Satoh, J.-I., Kino, Y., Yamamoto, Y., Kawana, N., Ishida, T., Saito, Y., & Arima, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0070-5 · Cited by 50
“Recently, whole-exome sequencing studies discovered rare functional variants located in Aβ precursor protein (APP), triggering receptor expressed on myeloid cells 2 (TREM2), and phospholipase D3 (PLD3) genes that exhibit a much greater contribution to protection or development of AD [3-5].”
Insights into Aβ Aggregation: A Molecular Dynamics Perspective
Shea, J., & Urbanc, B. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611212220012 · Cited by 52
Raskatov, J. A., & Teplow, D. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-10525-5 · Cited by 57
Sassi, C., Nalls, M. A., Ridge, P. G., Gibbs, J. R., Lupton, M. K., Troakes, C., Lunnon, K., Al-Sarraj, S., Brown, K. S., Medway, C., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.015 · Cited by 50
Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function
Zhu, K., Peters, F., Filser, S., & Herms, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.022 · Cited by 51
A rare missense variant of CASP7 is associated with familial late‐onset Alzheimer's disease
Zhang, X., Zhu, C., Beecham, G., Vardarajan, B. N., Ma, Y., Lancour, D., Farrell, J. J., Chung, J., Alzheimer's Disease Sequencing Project, Mayeux, R., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.005 · Cited by 55
“Recently, studies that performed whole exome sequencing (WES), targeting gene sequencing and rapid throughput genotyping using single nucleotide polymorphism microarray chips with high exome content, have reported associations with rare risk variants in multiple novel loci including TREM2 [8–10], PLD3 [11], AKAP9 [12]…”
Sacher, C., Blume, T., Beyer, L., Peters, F., Eckenweber, F., Sgobio, C., Deussing, M., Albert, N. L., Unterrainer, M., Lindner, S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227322 · Cited by 51
“The identification of familial AD mutations in the amyloid precursor protein (APP) gene has led to the generation of several transgenic mouse models that overexpress APP (7,8).”
BackgroundDistribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population
Lim, E. T., Würtz, P., Havulinna, A. S., Palta, P., Tukiainen, T., Rehnström, K., Esko, T., Mägi, R., Inouye, M., Lappalainen, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004494 · Cited by 49
“5–5%) variants in complex diseases and traits such as triglycerides [1], insulin processing [2], bone mineral density [3], Alzheimer’s disease [4], impulsivity [5], and prostate cancer [6], some of which confer protection from disease [4].”
BackgroundSelf-citationIs sleep disruption a risk factor for Alzheimer's disease?
Macedo, A. C., Balouch, S., & Tabet, N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161287 · Cited by 49
“Findings revealing that a change of 25-40% in Aβ production can either protect or accelerate the development of AD [37, 38], suggesting that sleep disruption may potentially play an important role in contributing to AD pathogenesis.”
Yadav, D. B., Maloney, J. A., Wildsmith, K. R., Fuji, R. N., Meilandt, W. J., Solanoy, H., Lu, Y., Peng, K., Wilson, B., Chan, P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14021 · Cited by 49
“, 2002), and reduced Aβ production has been associated with protection from Alzheimer’s disease (Jonsson et al., 2012; Maloney et al., 2014), making BACE1 inhibition promising as a disease-modifying therapy.”
BackgroundSelf-citationFuture Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Evin, G. M. (2016) · BioDrugs · doi:10.1007/s40259-016-0168-3 · Cited by 56
“hypothesis, a very rare APP mutation that was identified in Icelandic families and which favours APP processing through the non-amyloidogenic pathway seems to protect its carriers from developing AD in their old age [37].”
BackgroundThe advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 57
“…APP substitution found in very rare Scandinavian families protects its carriers from AD, and even from age-related cognitive decline in general, by decreasing the initial cleavage of APP by β-secretase (BACE1) by 30–40% and making the peptides that are still produced less prone to aggregation 33 .”
Hall, A., & Patel, T. R. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00003-2 · Cited by 51
Alzheimer’s Disease, Anesthesia, and Surgery: A Clinically Focused Review
Berger, M., Burke, J. R., Eckenhoff, R. G., & Mathew, J. P. (2014) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2014.04.014 · Cited by 53
Ohno, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.007 · Cited by 55
Pathway and network-based strategies to translate genetic discoveries into effective therapies
Greene, C. S., & Voight, B. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw160 · Cited by 50
Excess APP O -glycosylation by GalNAc-T6 decreases Aβ production
Akasaka‐Manya, K., Kawamura, M., Tsumoto, H., Saito, Y., Tachida, Y., Kitazume, S., Hatsuta, H., Miura, Y., Hisanaga, S., Murayama, S., et al. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw056 · Cited by 55
“This mutant APP results in a reduction of Ab production by 40% (44, 45), suggesting that O-glycosylation at Thr673 inhibits shedding by BACE1 or promotes TACE activity.”
BackgroundThe role of amyloidogenic protein oligomerization in neurodegenerative disease
Lotz, G., & Legleiter, J. (2013) · Journal of molecular medicine · doi:10.1007/s00109-013-1025-1 · Cited by 44
“A recent study has shown that a coding mutation (A673T) in the APP gene protects against AD [151].”
TREM2 expression and amyloid‐beta phagocytosis in Alzheimer's disease
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108626 · Cited by 50
Discrete Molecular Dynamics Study of Oligomer Formation by N-Terminally Truncated Amyloid β-Protein
Meral, D., & Urbanc, B. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.010 · Cited by 48
“Recently, two Aβ mutations at position 2 (Ala2Val and Ala2Thr) were found to significantly alter the resulting Aβ toxicity, thereby supporting this hypothesis [79, 80].”
ResultKalimo, H., Lalowski, M., Bogdanovic, N., Philipson, O., Bird, T. D., Nochlin, D., Schellenberg, G. D., Brundin, R., Olofsson, T., Soliymani, R., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-60 · Cited by 48
“Α2Τ in Aβ peptide) further suggests that Aβ is pivotal for the disease development [1].”
BackgroundThe rise and fall of insulin signaling in Alzheimer’s disease
Chami, B., Steel, A. J., de la Monte, S. M., & Sutherland, G. T. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9806-1 · Cited by 55
Soares, H. D., Gasior, M., Toyn, J. H., Wang, J.-S., Hong, Q., Berisha, F., Furlong, M. T., Raybon, J., Lentz, K. A., Sweeney, F., et al. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232256 · Cited by 46
“In addition, some APP mutations that reduce amyloid peptide formation (Jonsson et al., 2012) are protective.”
Nie, X., Zhang, Z., Wang, C., Fan, Y., Meng, Q.-Y., & You, Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00805 · Cited by 48
Application of next-generation sequencing technologies in Neurology.
Jiang, T., Tan, M., Tan, L., & Yu, J. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.11.11 · Cited by 61
“A676T) that protects against cognitive decline in the elderly without AD (13).”
BackgroundAttar, A., & Bitan, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990496 · Cited by 51
“Based on the surprising findings that substitution of K16 by A led to a dramatic loss of toxicity in both A 40 and A 42, we predict that mutations in app leading to this or similar substitutions may be found to be protective from AD, similar to the recently discovered protective mutation that causes an A2T substitutio…”
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Neuronal spreading and plaque induction of intracellular Aβ and its disruption of Aβ homeostasis
Roos, T. T., Garcia, M. G., Martinsson, I., Mabrouk, R., Israelsson, B., Deierborg, T., Kobro‐Flatmoen, A., Tanila, H., & Gouras, G. K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02345-9 · Cited by 55
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 49
Rarity of the Alzheimer Disease–Protective APP A673T Variant in the United States
Wang, L.-S., Naj, A. C., Graham, R. R., Crane, P. K., Kunkle, B. W., Cruchaga, C., Murcia, J. D. G., Cannon-Albright, L., Baldwin, C. T., Zetterberg, H., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2157 · Cited by 47
Self-citationDas, P., Chacko, A. R., & Belfort, G. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00357 · Cited by 48
From Common to Rare Variants: The Genetic Component of Alzheimer Disease
Nicolas, G., Charbonnier, C., & Campion, D. (2016) · Human Heredity · doi:10.1159/000452256 · Cited by 51
Pousinha, P. A., Mouska, X., Raymond, E., Gwizdek, C., Dhib, G., Poupon, G., Zaragosi, L., Giudici, C., Bethus, I., Pacary, E., et al. (2017) · eLife · doi:10.7554/elife.25659 · Cited by 51
“In humans, a polymorphism in APP that reduces APP processing protects from sporadic Alzheimer’s disease (AD) and normal aging-dependent decline (Supplementary file 1; Jonsson et al., 2012).”
BackgroundZhang, L., Trushin, S., Christensen, T. A., Tripathi, U., Hong, C. C., Geroux, R. E., Howell, K. G., Poduslo, J. F., & Trushina, E. V. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.003 · Cited by 59
Early Intervention in Alzheimer’s Disease: How Early is Early Enough?
Fan, D., & Wang, Y.-J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00429-x · Cited by 51
Tambini, M. D., Norris, K. A., & D'Adamio, L. (2020) · eLife · doi:10.7554/elife.52612 · Cited by 50
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders
Marchi, F. D., Munitić, I., Vidatic, L., Papić, E., Rački, V., Nimac, J., Jurak, I., Novotni, G., Rogelj, B., Vuletić, V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102793 · Cited by 54
Eph receptors: New players in Alzheimer's disease pathogenesis
Cissé, M., & Checler, F. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.028 · Cited by 46
Epstein, O. I., Bryan, M. C., Cheng, A. C., Derakhchan, K., Dineen, T. A., Hickman, D., Hua, Z., Human, J. B., Kreiman, C. R., Marx, I. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501266w · Cited by 48
Butler, C. R., Brodney, M. A., Beck, E. M., Barreiro, G., Nolan, C. E., Pan, F., Vajdos, F. F., Parris, K. D., Varghese, A. H., Helal, C. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501833t · Cited by 50
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
Marino, M., Zhou, L., Rincón, M. Y., Callaerts‐Vegh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K. D. B., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 48
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M., Pihlajamäki, J., Soininen, H., & Hiltunen, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 46
“This idea is further supported by the recent proof-of-concept finding, which indicated that a naturally occurring, low-frequency variant A673T in APP protects from the AD- and age-related cognitive decline by lowering the production of Ab through reduced BACE1-mediated cleavage of APP [124].”
ResultAn effective treatment for Alzheimer's disease must consider both amyloid and tau
Lansdall, C. J. (2014) · Bioscience Horizons · doi:10.1093/biohorizons/hzu002 · Cited by 46
“Interestingly, protective mutations such as the A673T variant of APP, result in a 20% reduction in lifelong production of Aβ and prevent individuals from developing cognitive impairments and AD (Jonsson et al., 2012).”
BackgroundButler, C. R., Ogilvie, K., Martinez-Alsina, L., Barreiro, G., Beck, E. M., Nolan, C. E., Atchison, K. P., Benvenuti, E., Buzon, L. M., Doran, S. D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01451 · Cited by 48
Systems healthcare: a holistic paradigm for tomorrow
Fiandaca, M. S., Mapstone, M. E., Connors, E. E., Jacobson, M., Monuki, E. S., Malik, S., Macciardi, F. M., & Federoff, H. J. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0521-2 · Cited by 54
MicroRNA-132 is associated with the cognition improvement following voluntary exercise in SAMP8 mice
Dong, J., Liu, Y., Zhan, Z., & Wang, X. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.04.007 · Cited by 46
Self-citationPassive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J.-U., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 45
“Protective mutations have also been described, which lead to reduced cleavage of APP and thus the lowering of Aβ production and the risk for development of dementia [18].”
BackgroundBi, C., Bi, S., & Li, B. (2018) · Aging and Disease · doi:10.14336/ad.2018.0425 · Cited by 52
“Aβ40 and Aβ42 all decreased; the ratio of Aβ42/Aβ40 all did not change; Aβ40 and Aβ42 polymerization decreased [70-74].”
Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2
Hsu, S., Pimenova, A. A., Hayes, K., Villa, J. A., Rosene, M. J., Jere, M., Goate, A. M., & Karch, C. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104817 · Cited by 47
“A rare variant in APP, APP A673T, has been reported to confer protection against AD risk (Jonsson et al., 2012; Maloney et al., 2014).”
BackgroundGenetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities
Gabriele, R. M. C., Abel, E., Fox, N. C., Wray, S., & Arber, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.835645 · Cited by 44
“, 2016) and mutations that reduce amyloidogenic processing of APP can be protective against AD (Jonsson et al., 2012).”
BackgroundPetralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
“Mutations in and around the A β region of APP lead to FAD [25–27], while mutations in the same APP gene that decrease A β production are protective against AD [28].”
BackgroundDown syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology
Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 54
A Profile of Residents in Prairie Nursing Homes
Estabrooks, C. A., Poss, J. W., Squires, J. E., Teare, G. F., Morgan, D., Stewart, N. J., Doupe, M. B., Cummings, G. G., & Norton, P. (2013) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980813000287 · Cited by 44
Chen, K.-F., Possidente, B., Lomas, D. A., & Crowther, D. C. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014134 · Cited by 44
“…mutations that dysregulate APP processing: mutations that result in a spectrum of Aβ peptides with a higher aggregation propensity have been linked to familial AD (Philipson et al., 2010), whereas sequence variation in APP that reduces Aβ production is protective (Jonsson et al., 2012).”
BackgroundAudrain, M., Fol, R., Dutar, P., Potier, B., Billard, J.-M., Flament, J., Alves, S., Burlot, M.-A., Dufayet-Chaffaud, G., Bemelmans, A.-P., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0070-y · Cited by 43
“Amyloid Precursor Protein (APP) is a key element in its development [5].”
BackgroundNguyen, P. H., Sterpone, F., Pouplana, R., Derreumaux, P., & Campanera, J. M. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b10722 · Cited by 44
Integrated Analysis of Whole Exome Sequencing and Copy Number Evaluation in Parkinson’s Disease
Alyemni, E. A., Monies, D., Alkhairallah, T., Bohlega, S., Abouelhoda, M. I., Magrashi, A. I., Mustafa, A., Al-Abdulaziz, B., Al‐Hamed, M. H., Baz, B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40102-x · Cited by 46
The Role of APP O-Glycosylation in Alzheimer’s Disease
Akasaka-Manya, K., & Manya, H. (2020) · Biomolecules · doi:10.3390/biom10111569 · Cited by 44
“The A673T mutation was reported to reduce APP β-secretase cleavage and consequently Aβ production [88].”
BackgroundInfluentialRational heterodoxy: Cholesterol reformation of the amyloid doctrine
Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.007 · Cited by 45
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Volloch, V., & Rits‐Volloch, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230164 · Cited by 50
“Both are capable of multiple cleavages within iA (reviewed in [5]), a capacity enhanced in BACE1 by the Icelandic A PP mutation [16, 17] (explaining its protective action) and suppressed in BACE2 by the Flemish A PP mutation [18] (thus causing familial AD).”
BackgroundThe impact of rare genetic variants on Alzheimer disease
Deyn, L. D., & Sleegers, K. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01062-1 · Cited by 50
“Of note, not all rare variants are risk increasing: several protective variants have been described 25–28 .”
Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer’s disease
Gentier, R. J. G., & van Leeuwen, F. W. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00047 · Cited by 49
Toward the structure of presenilin/γ-secretase and presenilin homologs
Wolfe, M. S. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.015 · Cited by 51
“Most recently, an APP mutation near the β-secretase cleavage site that leads to reduced Aβ production was found to be protective for Alzheimer's disease [16].”
BackgroundMandal, M., Wu, Y., Misiaszek, J., Li, G., Buevich, A. V., Caldwell, J. P., Liu, X., Mazzola, R., Orth, P., Strickland, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01995 · Cited by 45
State of Play in Alzheimer’s Disease Genetics
Zhu, J.-B., Tan, C.-C., Tan, L., & Yu, J.-T. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170062 · Cited by 43
“A mutation (A673T) in APP has been reported 120 to reduce AD risk from a study in the Icelandic pop121 ulation [8].”
O’Neill, B. T., Beck, E. M., Butler, C. R., Nolan, C. E., Gonzales, C., Zhang, L., Doran, S. D., Lapham, K., Buzon, L. M., Dutra, J. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00246 · Cited by 42
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 53
“population with AD, which indicated that a reduction of cleavage of APP might protect against AD [13].”
BackgroundSelf-citationWang, L., & Liu, Z.-P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00157 · Cited by 47
“Relationship Between Biomarkers and AD Genes Although APP (Jonsson et al., 2012), APOE (Morris et al.”
BackgroundListe, I., Coronel, R., Palmer, C., Bernabeu-Zornoza, A., Monteagudo, M., Rosca, A., & Zambrano, A. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257511 · Cited by 42
“In addition, as discussed above, mutations in the APP gene (with the exception of A673T mutation) (Jonsson et al., 2012) are associated with the appearance of familial AD, since they all favor the production of Aβ peptide (Van Dam and De Deyn, 2006).”
BackgroundYasukawa, T., Tsutsui, A., Tomomori‐Sato, C., Sato, S., Saraf, A., Washburn, M. P., Florens, L. A., Terada, T., Shimizu, K., Conaway, R., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.059 · Cited by 46
Hung, C., Fertan, E., Livesey, F. J., Klenerman, D., & Patani, R. (2024) · Brain · doi:10.1093/brain/awae092 · Cited by 44
“4 These findings strongly implicate overexpression of APP protein as one pathomechanism of AD.”
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 53
GPR3 Stimulates Aβ Production via Interactions with APP and β-Arrestin2
Nelson, C. D., & Sheng, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074680 · Cited by 45
Durand, E. Y., Eriksson, N., & McLean, C. Y. (2014) · Molecular Biology and Evolution · doi:10.1093/molbev/msu151 · Cited by 44
“IBD segments have been used to identify disease genes (Krawitz et al. 2010; Gusev et al. 2011; Jonsson et al. 2012) and estimate the heritability of traits and common diseases (Visscher et al. 2006; Zuk et al. 2012).”
BackgroundMethod
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.